ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -49.10M | -54.37M | -34.68M | -89.48M | -32.95M | |||
| Depreciation Amortization | 63.00K | 73.00K | 320.00K | 780.00K | 640.00K | |||
| Change In Working Capital | -1.90M | -7.33M | -12.75M | 1.60M | -2.63M | |||
| Interest Paid | N/A | 0.00 | 370.00K | N/A | N/A | |||
| Other non cash items | 5.08M | 2.36M | 7.04M | 20.34M | 3.74M | |||
| OPERATING CASH FLOW | -45.86M | -59.27M | -40.08M | -66.76M | -31.20M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -166.00K | -175.00K | -200.00K | -1.37M | -920.00K | |||
| Other Investing Activity | 21.86M | -87.00M | N/A | -65.11M | N/A | |||
| INVESTING CASH FLOW | 21.70M | -87.18M | -200.00K | -66.48M | -920.00K | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | 0.00 | -8.68M | -850.00K | -700.00K | |||
| Stock Issued/Repurchased | 3.29M | 6.90M | 570.00K | 1.46M | 411.81M | |||
| Other Financing Activity | N/A | 0.00 | 198.84M | 0.00 | -2.61M | |||
| FINANCING CASH FLOW | 3.29M | 6.90M | 190.73M | 610.00K | 408.51M | |||
| CHANGE IN CASH | -20.87M | -139.55M | 150.45M | -132.63M | 376.39M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -45.86M | -59.27M | -40.08M | -66.76M | -31.20M | |||
| Capital Expenditure | -166.00K | -175.00K | -200.00K | -1.37M | -920.00K | |||
| FREE CASH FLOW | -46.03M | -59.44M | -40.28M | -68.13M | -32.12M | |||
All data in USD